Matches in SemOpenAlex for { <https://semopenalex.org/work/W2081902857> ?p ?o ?g. }
- W2081902857 endingPage "1520" @default.
- W2081902857 startingPage "1508" @default.
- W2081902857 abstract "As deregulation of RAS signaling is important in the pathogenesis of myeloid leukemias, molecular targeting of RAS signaling may be a promising therapeutic strategy. Farnesyl transferase inhibitors (FTIs) are the most promising class of these new cancer therapeutics. Several FTIs have entered phase II clinical trials in acute myeloid leukemia (AML). Since geranylgeranylation of K-RAS and N-RAS in the presence of FTIs may represent an important mechanism of FTI resistance, 6 geranylgeranyl transferase-I inhibitors (GGTIs) were screened alone and in combination with FTI for growth inhibition of myeloid leukemia cells. Significant growth inhibition (>70%) in myeloid cell lines was observed for GGTI-286 (9/19), GGTI-298 (14/19), GGTI-2147 (16/19) and FTI L-744,832 (17/17). GGTI treatment of NB-4 cells resulted in an accumulation of cells in G0/G1, whereas FTI L-744,832 primarily caused an increase in G2/M. FTI and GGTIs both induced apoptosis. In all cases, FTI/GGTI cotreatment led to synergistic cytotoxic effects in both myeloid cell lines (5/5) and primary AML cells (6/6). This synergy coincided with increased apoptosis. FTI/GGTI cotreatment caused an accumulation of unprocessed N-RAS and inactive N-RAS–RAF complexes. Our results suggest that alternative geranylgeranylation of N-RAS may represent an important mechanism of resistance to FTI monotherapy in myeloid leukemia cells." @default.
- W2081902857 created "2016-06-24" @default.
- W2081902857 creator A5008944165 @default.
- W2081902857 creator A5011083669 @default.
- W2081902857 creator A5013231760 @default.
- W2081902857 creator A5065954380 @default.
- W2081902857 creator A5081076272 @default.
- W2081902857 date "2003-07-29" @default.
- W2081902857 modified "2023-10-16" @default.
- W2081902857 title "Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors" @default.
- W2081902857 cites W1491433568 @default.
- W2081902857 cites W1506096984 @default.
- W2081902857 cites W1569327468 @default.
- W2081902857 cites W1580959101 @default.
- W2081902857 cites W1598598013 @default.
- W2081902857 cites W194463696 @default.
- W2081902857 cites W1965995529 @default.
- W2081902857 cites W1970338715 @default.
- W2081902857 cites W1974624332 @default.
- W2081902857 cites W1975702431 @default.
- W2081902857 cites W1980981080 @default.
- W2081902857 cites W1985238450 @default.
- W2081902857 cites W1988409513 @default.
- W2081902857 cites W1996254906 @default.
- W2081902857 cites W1996993759 @default.
- W2081902857 cites W1998216249 @default.
- W2081902857 cites W1999175477 @default.
- W2081902857 cites W2005564932 @default.
- W2081902857 cites W2006525926 @default.
- W2081902857 cites W2007963672 @default.
- W2081902857 cites W2010577277 @default.
- W2081902857 cites W2011425688 @default.
- W2081902857 cites W2011956142 @default.
- W2081902857 cites W2016644494 @default.
- W2081902857 cites W2017098460 @default.
- W2081902857 cites W2017550542 @default.
- W2081902857 cites W2018724145 @default.
- W2081902857 cites W2019687915 @default.
- W2081902857 cites W2029079353 @default.
- W2081902857 cites W2036699032 @default.
- W2081902857 cites W2043578693 @default.
- W2081902857 cites W2043692783 @default.
- W2081902857 cites W2051203902 @default.
- W2081902857 cites W2051626784 @default.
- W2081902857 cites W2054591128 @default.
- W2081902857 cites W2060957113 @default.
- W2081902857 cites W2061234826 @default.
- W2081902857 cites W2066254967 @default.
- W2081902857 cites W2070023258 @default.
- W2081902857 cites W2070622053 @default.
- W2081902857 cites W2077945404 @default.
- W2081902857 cites W2085191274 @default.
- W2081902857 cites W2096910536 @default.
- W2081902857 cites W2102901804 @default.
- W2081902857 cites W2153825396 @default.
- W2081902857 cites W2154468846 @default.
- W2081902857 cites W2156654096 @default.
- W2081902857 cites W2157502463 @default.
- W2081902857 cites W2163985137 @default.
- W2081902857 cites W2165533554 @default.
- W2081902857 cites W2176744910 @default.
- W2081902857 cites W2187613426 @default.
- W2081902857 cites W2255894651 @default.
- W2081902857 cites W2296905683 @default.
- W2081902857 cites W2316903752 @default.
- W2081902857 cites W4230045015 @default.
- W2081902857 cites W4233391937 @default.
- W2081902857 cites W4243003607 @default.
- W2081902857 cites W4246129764 @default.
- W2081902857 cites W4293247451 @default.
- W2081902857 doi "https://doi.org/10.1038/sj.leu.2403022" @default.
- W2081902857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12886237" @default.
- W2081902857 hasPublicationYear "2003" @default.
- W2081902857 type Work @default.
- W2081902857 sameAs 2081902857 @default.
- W2081902857 citedByCount "31" @default.
- W2081902857 countsByYear W20819028572012 @default.
- W2081902857 countsByYear W20819028572013 @default.
- W2081902857 countsByYear W20819028572014 @default.
- W2081902857 countsByYear W20819028572015 @default.
- W2081902857 countsByYear W20819028572016 @default.
- W2081902857 countsByYear W20819028572019 @default.
- W2081902857 countsByYear W20819028572022 @default.
- W2081902857 crossrefType "journal-article" @default.
- W2081902857 hasAuthorship W2081902857A5008944165 @default.
- W2081902857 hasAuthorship W2081902857A5011083669 @default.
- W2081902857 hasAuthorship W2081902857A5013231760 @default.
- W2081902857 hasAuthorship W2081902857A5065954380 @default.
- W2081902857 hasAuthorship W2081902857A5081076272 @default.
- W2081902857 hasBestOaLocation W20819028571 @default.
- W2081902857 hasConcept C181199279 @default.
- W2081902857 hasConcept C203014093 @default.
- W2081902857 hasConcept C23167141 @default.
- W2081902857 hasConcept C2777827897 @default.
- W2081902857 hasConcept C2778396349 @default.
- W2081902857 hasConcept C2778461978 @default.
- W2081902857 hasConcept C2778729363 @default.
- W2081902857 hasConcept C2779282312 @default.